NEW YORK–(BUSINESS WIRE)–Massive organic, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. Supported by Series B investments received during the first half of this year, Massive Bio announced the addition of three new team members who will help expand the company’s global operations, ramp up its marketing efforts, develop new datasets and products, and to expand its mergers and acquisitions efforts. The newcomers are toy gun onaran, who serves as Head of Strategy; Mert Sari, who will regional manager; and Sinan Findikwho comes on board Clinical research and data manager.
Massive Bio’s growing presence in Europe will allow the company to continue its mission of ensuring all cancer patients receive treatment under fair and affordable conditions, he said Caglar Demirbag, Director of International Partnerships, who directs the company’s operations outside the US, added, “Approximately 4 million patients are diagnosed with cancer in Europe each year. With the steps we have taken over the past two years, we have ensured that thousands of cancer patients in Spain, Italy, France, Germany, Romania, Poland and Greece receive appropriate clinical trials. This also allows these patients to receive the best treatment for free.”
“The current changes we are making today will help us better reach and support more cancer patients in the future,” he added Ercan Terzi, Vice President of Global Marketing at Massive Bio. Terzi said: “At Massive Bio, we work across 32 different functional areas in our marketing efforts on three continents. Our recent updates, newsletters, infographics, new video production, digital asset improvements, content writing and advertising management continue to help us create a more comprehensive and effective use case for patients. The technologies we use and the integrated studies we create with different entities allow us to work more effectively in business focus.”
About Massive Bio
Founded in 2015 in New York City, Massive Bio’s mission is to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial situation.